Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PRKACG | P22612 | 1/20 | 0.41 |
| ▸ | PRKACB | P22694 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | PRKCG | P05129 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904324 | 0.82 | GAA (0.48) | HRH3PRKCBPRKCAPRKCE | |
| SCHEMBL2907165 | 0.81 | GSK3B (0.47) | RAD52HRH3KAT2BACP1PRKCB | |
| SCHEMBL2902498 | 0.77 | KAT2B (0.43) | PRKACAPRKACGPRKACBKAT2BPRKCA | |
| SCHEMBL2908633 | 0.77 | PRKCA (0.48) | RAD52NPC1RAB9APRKACAPRKACG | |
| SCHEMBL2905932 | 0.76 | GAA (0.52) | NPC1RAB9AHRH1PRKACAPRKACG | |
| SCHEMBL2909220 | 0.69 | CDK2 (0.50) | NPC1RAB9APRKCA | |
| SCHEMBL2908034 | 0.67 | ALDH1A1 (0.48) | NPC1RAB9APRKCA | |
| SCHEMBL6525014 | 0.65 | RAD52 (0.59) | RAD52NPC1RAB9AERAP1CAMK2D | |
| SCHEMBL2902665 | 0.64 | GAA (0.49) | NPC1RAB9AHRH1MITFPRKCG | |
| SCHEMBL27286416 | 0.64 | HTR6 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874761-B1 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | claimed |
| EP-1874761-B1 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | disclosed |
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
| EP-1874761-A2 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | Aventis Pharma S.A. (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111662-A2 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | AVENTIS PHARMA S.A. (FR) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | CYP11B2, IL5, TBXA2R | RAD52 2286/4885NPC1 798/4885RAB9A 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.